Regeneron

YTD

ALL

Trade Regeneron 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About REGN

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara.

CEO

Leonard S. Schleifer

CEOLeonard S. Schleifer

Employees

15,410

Employees15,410

Headquarters

Tarrytown, New York

HeadquartersTarrytown, New York

Founded

1988

Founded1988

Employees

15,410

Employees15,410

REGN Key Statistics

Market cap

78.86B

Market cap78.86B

Price-Earnings ratio

18.18

Price-Earnings ratio18.18

Dividend yield

0.47%

Dividend yield0.47%

Average volume

659.43K

Average volume659.43K

High today

$755.64

High today$755.64

Low today

$742.69

Low today$742.69

Open price

$749.56

Open price$749.56

Volume

505.26K

Volume505.26K

52 Week high

$821.11

52 Week high$821.11

52 Week low

$476.49

52 Week low$476.49

Stock Snapshot

Regeneron(REGN) stock is priced at $743.00, giving the company a market capitalization of 78.86B. It carries a P/E multiple of 18.18 and pays a dividend yield of 47.5%.

During the trading session on 2026-04-16, Regeneron(REGN) shares reached a daily high of $755.64 and a low of $742.69. At a current price of $743.00, the stock is +0.0% higher than the low and still -1.7% under the high.

Trading activity shows a volume of 505.26K, compared to an average daily volume of 659.43K.

The stock's 52-week range extends from a low of $476.49 to a high of $821.11.

REGN News

Simply Wall St 6h

Regeneron’s Dupixent Win And Telix Deal Add New Layers To Valuation

The European Commission approved Dupixent as the first targeted treatment for moderate to severe chronic spontaneous urticaria in children aged 2 to 11 across t...

Simply Wall St 1d

A Look At Regeneron Pharmaceuticals Valuation After New Telix Radiopharmaceutical Collaboration

Regeneron Pharmaceuticals (REGN) just expanded its oncology reach through a new collaboration with Telix Pharmaceuticals to co-develop radiopharmaceutical thera...

Benzinga 4d

Telix Pharma Gains As Regeneron Tie-Up Targets Solid Tumor Programs

Regeneron is a U.S.-based integrated biotechnology company, and Telix is a radiopharmaceutical company. Partnership Combines Platforms And Scientific Capabilit...

Analyst ratings

77%

of 31 ratings

Buy

77.4%

Hold

22.6%

Sell

More REGN News

Nasdaq 4d

Regeneron Pharma Partners Telix Pharma To Jointly Develop Radiopharmaceutical Therapies

(RTTNews) - Regeneron Pharmaceuticals, Inc. (REGN) and Telix Pharmaceuticals Ltd. (TLX, TLX.AX) announced Monday a collaboration to jointly develop and commerci...

TipRanks 4d

Telix Pharmaceuticals up 11% to $11.70 after collaboration with Regeneron

06:36 EDT Telix Pharmaceuticals (TLX) up 11% to $11.70 after collaboration with Regeneron (REGN) Unlock hedge fund-level data and powerful investing tools for...

People also own

Based on the portfolios of people who own REGN. This list is generated using Robinhood data, and it’s not a recommendation.

MercadoLibre

abrdn Physical Precious M…

Moody's

Cipher Mining

Grab

Brookfield Corporation

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.